A recent article from Hemp Industry Daily wondered what the future holds for CBD with the recent resignation of FDA Commissioner Scott Gottlieb. The miracle molecule, CBD, continues to gain in popularity across the country. So whatever the FDA has to say on the topic of regulating an infant industry at this point in the game is important. Mixed reactions are coming from the hemp world.
From the article:
“Hemp is too important to this country’s farmers, small business owners and consumers to allow its forward movement to be stalled due to one person,” said Bob Crumley, CEO of Founder’s Hemp in North Carolina. “The FDA must not use this resignation to slow down hemp’s growth.”
“Startups and investors need assurance that they are going in the right direction, and I’m certain most want to be compliant with whatever regulations are put in place,” he said.
“Gottlieb’s evolving position on CBD is more a reflection of where the agency, the Trump Administration and, frankly, where Washington is,” Miller said. “I’m confident that whoever replaces Gottlieb will face the same sort of congressional pressure to get this resolved in favor of promoting the whole retail sale of CBD.”
Many believe that whatever happens with the appointment of a new FDA Commissioner, hemp derived CBD is here to stay. The benefits are already well known to many, but the masses are just waking up to how CBD can improve their lives. The federal government and private institutions are studying CBD and its effects on the human body. Results of studies are released on a frequent basis and will likely increase as the industry continues to grow.
But whatever happens with the appointment, the rulemaking meeting scheduled for April will still occur. The FDA has been pressed too hard by different parties to delay industry regulations with the explosive growth of the industry.